Borregaard (BRG) SEB Nordic Seminar presentation summary
Event summary combining transcript, slides, and related documents.
SEB Nordic Seminar presentation summary
16 Jan, 2026Company background and market position
Founded in 1889 in Norway, with over 135 years of experience and a history as one of Norway's largest companies for over 60 years.
Operates the world's most advanced biorefinery, fully utilizing sustainable Norway Spruce as raw material.
Employs 1,150 people, with business in 13 countries and sales to 100 countries, generating 7.6 billion NOK turnover and 1.9 billion NOK EBITDA.
Business model, strategy, and innovation
Biorefinery model focuses on high value-added products through full raw material utilization and diversified markets.
Specializes as a global niche player in markets with high entry barriers, leveraging application knowledge and proximity to markets.
Strong innovation and continuous improvement are core, with competence as a key competitive advantage.
Strategic priorities include increased specialisation, value growth, and targeted investments in capacity and new initiatives.
Product portfolio and market reach
Leading supplier of lignin-based biopolymers, only producer of wood-based vanillin, and pioneer in cellulose fibrils.
Product applications span agriculture, construction, food & pharma, chemicals, and fine chemicals.
Sales distribution in 2024: Europe 46%, Americas 30%, Asia 23%, Rest of World 1%.
Latest events from Borregaard
- EBITDA fell 16% year-over-year as cost inflation and weaker BioSolutions weighed on results.BRG
Q1 202629 Apr 2026 - Specialisation, innovation, and sustainability drive growth and strong financial performance.BRG
Company presentation29 Apr 2026 - Specialisation, sustainability, and innovation drive growth and value in advanced biorefinery markets.BRG
Company presentation29 Apr 2026 - AGM approved a 12% dividend increase, board renewal, and strong financial and sustainability plans.BRG
AGM 202624 Apr 2026 - BioMaterials and BioSolutions volumes to grow in 2026, but pricing and cost risks persist.BRG
Pre-close call19 Mar 2026 - Record EBITDA, strong cash flow, higher dividend, and start-up impairments define the period.BRG
Q4 20254 Feb 2026 - BioSolutions strength offset weaker BioMaterials; outlook cautious amid rising costs.BRG
Q2 20243 Feb 2026 - Specialization, innovation, and sustainability drive robust growth and disciplined investment.BRG
CMD 202420 Jan 2026 - Q3 revenue and EBITDA rose on volume growth and expansion, but cost and market risks remain.BRG
Q3 202417 Jan 2026